Baxter International has seen its share price move around sharply over the past few years, which naturally raises a question for anyone looking at the stock today. Are the cash flows that Baxter can generate over time enough to support the current valuation implied by a recent close around US$23.50?
- The share price has fallen 66.9% over the past 5 years, which puts the focus squarely on whether the underlying cash flows still justify owning Baxter at all.
- Recent news has pulled the business in two directions because a U.S. FDA warning letter highlights potential compliance driven costs while new connected vital signs technology in markets such as Qatar may support longer term cash generation from Baxter's medical products portfolio.
- If you'd rather focus on sales, this one's for you. See what Baxter International's 1.1x P/S says about the price.
The issue now is whether the cash flows implied by Baxter International's current valuation line up with what investors are actually paying for at today’s share price.
If you are evaluating Baxter International based solely on its cash flows and risk profile, it can be helpful to compare it with a broader group of 30 resilient stocks with low risk scores.
Is Baxter International a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model here looks at what Baxter International might deliver in future free cash to shareholders and then brings those amounts back to today. On the latest figures, the group generated roughly $850.3 million of free cash flow over the last twelve months, and the model projects a gradual increase in annual cash generation over the coming decade rather than a sharp ramp up or decline. That pattern fits a mature healthcare supplier, where incremental gains in efficiency and product adoption matter more than big swings in capital spending.
These steady cash projections, when discounted, point to an estimated intrinsic value that sits substantially above the current share price of $23.50. The recent FDA warning letter on contamination controls helps explain why the market keeps Baxter International priced where it is despite those cash flow assumptions. The cash-based valuation work suggests investors are paying less for the equity than the DCF model implies it might be worth over time. Find out what Baxter International could be worth using our Discounted Cash Flow (DCF) estimate.
The Baxter International Narrative: What Would Justify Today's Price?
Narratives on Simply Wall St take that valuation puzzle around Baxter International and spell out which paths for earnings, margins and growth would need to play out for the shares to be worth meaningfully more or less than today’s price on the Community page. Each scenario links its figures to a clear view of how Baxter International's growth prospects, profitability and key risks might change. This gives you something concrete to revisit as fresh information becomes available.
Community views on Baxter International pull in opposite directions, with one group seeing room in the valuation and another arguing expectations already look full.
Bull case: 16% undervalued
"Baxter International focus on decentralization and the Baxter Growth & Performance System, with hundreds of completed and ongoing continuous improvement events tied to divisional KPIs…"
Discover why this Narrative puts Baxter International at 16% undervalued.
Bear case: 18% overvalued
"Although Baxter International reports progress on decentralization and Baxter GPS continuous improvement, the latest 90 bps decline in adjusted operating margin to 14.2% and 210 bps decline in adjusted gross margin to 38.6% indicate that efficiency gains are not yet offsetting higher manufacturing costs and lower absorption…"
Explore why this Narrative puts Baxter International at 18% overvalued.
Before you weigh Baxter International purely on price, check what the risk filters are saying
Valuation is only half the story for Baxter International, because recent research screens have flagged specific concerns that deserve space in your thinking before you commit fresh capital. Take a closer look at 1 major warning sign before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com